Yarrow Bioscience, Inc. YARW
Yarrow Bioscience, Inc. (Nasdaq: YARW) is an endocrine/women's health drug developer. Its lead program, YB-101 (GenSci098), is in Phase 1 for Graves' disease; thyroid eye disease planned. Its next catalyst on record is VYN202: Final report of repeat non-clinical toxicology study in male dogs (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VYN202 — Final report of repeat non-clinical toxicology study in male dogs (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| repibresib | Topical pan-BET inhibitor; Phase 2b nonsegmental vitiligo trial terminated July 2025 | small molecule | Phase 2 |
| YB-101 (GenSci098) | Graves' disease and thyroid eye disease (TSHR antibody, clinical-stage) | antibody | Phase 1 |
| VYN202 | Immune-mediated inflammatory disease (oral BD2-selective BET inhibitor; Phase 1b terminated July 2025 after clinical hold; repeat dog tox study) | small molecule | Phase 1 |
Recent results and decisions
- May 20, 2026n/a FDA granted Fast Track designation to YB-101 in Graves' disease on May 20, 2026 (disclosed in business description exhibit).
Yarrow also submitted an application for Fast Track designation for YB-101 in GD to the FDA in March 2026 and received notice of Fast Track designation from the FDA on May 20, 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.